✦ LIBER ✦

1001 Nonpalpable, prostate-specific antigen detected prostatic carcinoma: Disease outcome after irradiation or radical prostatectomy

✍ Scribed by MG Haddock; TF Kozelsky; TM Pisansky

Book ID: 108435826
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 122 KB
Volume: 39
Category: Article
ISSN: 0360-3016
DOI: 10.1016/s0360-3016(97)80721-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Low Detectable Prostate Specific Antigen

Low Detectable Prostate Specific Antigen after Radical Prostatectomy—Treat or Watch?

✍ Koulikov, Dmitry; Mohler, Maura C.; Mehedint, Diana C.; Attwood, Kristopher; Wil 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 444 KB

Biochemical outcome after radical prosta

Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era

✍ Anthony V. D'Amico; Richard Whittington; S. Bruce Malkowicz; Kerri Cote; Marian 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

## Abstract ## BACKGROUND To the authors' knowledge, consensus is lacking regarding the relative long‐term efficacy of radical prostatectomy (RP) versus conventional‐dose external beam radiation therapy (RT) in the treatment of patients with clinically localized prostate carcinoma. ## METHODS A

Does Body Mass Index Affect Preoperative

Does Body Mass Index Affect Preoperative Prostate Specific Antigen Velocity or Pathological Outcomes After Radical Prostatectomy?

✍ Loeb, Stacy; Yu, Xiaoying; Nadler, Robert B.; Roehl, Kimberly A.; Han, Misop; Ha 📂 Article 📅 2007 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 71 KB

Rosiglitazone versus placebo for men wit

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy

✍ Matthew R. Smith; Judith Manola; Donald S. Kaufman; Daniel George; William K. Oh 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to assess the biologic activity of rosiglitazone, a peroxisome proliferator‐activated receptor γ agonist that has been approved to treat type 2 diabetes, in men with recurrent prostate carcinoma using change in prostate specific antigen (PS

25-Year Disease-Free Survival Rate After

25-Year Disease-Free Survival Rate After Irradiation for Prostate Cancer Calculated with the Prostate Specific Antigen Definition of Recurrence Used for Radical Prostatectomy

✍ Critz, Frank A.; Benton, James B.; Shrake, Philip; Merlin, Mark L. 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 482 KB

Pathologic findings and prostate specifi

Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a Gleason score ≤ 7

✍ Anthony V. D'Amico; Yuehui Wu; Ming-Hui Chen; Marc Nash; Andrew A. Renshaw; Jero 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views